Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

All right, everybody. We're going to get going here with our next company presenter at the BofA Annual Healthcare Conference. My name is Jason Gerberry. I cover pharma and biotech. And I'm pleased to ...

Cytokinetics Inc. CYTK shares are up on Tuesday as the company announced positive topline results from its pivotal Phase 3 ACACIA-HCM trial, which met both dual primary endpoints. The trial evaluated ...

A total of 54 infants with need for intensive care were monitored during the first days of life at the NICU of two different hospitals. Their recordings were collected in three different datasets. In ...

Abstract: Sleep apnea-hypopnea syndrome (SAHS) seriously affects human sleep, so it is necessary to find the disease as early as possible. However, most of traditional models use convolutional neural ...

Introduction Identifying acute hypercapnic respiratory failure is crucial in the initial management of acute exacerbations of COPD. Guidelines recommend obtaining arterial blood samples but these are ...

Objective: To establish the prevalence of chronotropic incompetence in a cohort of patients with chronic heart failure (CHF) taking modern medications for heart failure, and whether this affected ...